ID   DOPO_HUMAN              Reviewed;         617 AA.
AC   P09172; Q5T381; Q96AG2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   24-JUL-2007, sequence version 3.
DT   28-JUN-2023, entry version 227.
DE   RecName: Full=Dopamine beta-hydroxylase;
DE            EC=1.14.17.1 {ECO:0000269|PubMed:3443096, ECO:0000269|PubMed:7961964, ECO:0000269|PubMed:8546710};
DE   AltName: Full=Dopamine beta-monooxygenase;
DE   Contains:
DE     RecName: Full=Soluble dopamine beta-hydroxylase;
GN   Name=DBH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-617, PARTIAL PROTEIN SEQUENCE, VARIANTS
RP   THR-211 AND CYS-549, CATALYTIC ACTIVITY, FUNCTION, AND PATHWAY.
RX   PubMed=3443096; DOI=10.1002/j.1460-2075.1987.tb02734.x;
RA   Lamouroux A., Vigny A., Faucon Biguet N., Darmon M.C., Franck R.,
RA   Henry J.-P., Mallet J.;
RT   "The primary structure of human dopamine-beta-hydroxylase: insights into
RT   the relationship between the soluble and the membrane-bound forms of the
RT   enzyme.";
RL   EMBO J. 6:3931-3937(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3-617.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-617.
RX   PubMed=2922261; DOI=10.1093/nar/17.3.1089;
RA   Kobayashi K., Kurosawa Y., Fukita K., Nagatsu T.;
RT   "Human dopamine beta-hydroxylase gene: two mRNA types having different 3'-
RT   terminal regions are produced through alternative polyadenylation.";
RL   Nucleic Acids Res. 17:1089-1102(1989).
RN   [5]
RP   PROTEIN SEQUENCE OF 40-48, CATALYTIC ACTIVITY, FUNCTION, PATHWAY,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, COFACTOR, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=8546710; DOI=10.1042/bj3130057;
RA   Li B., Tsing S., Kosaka A.H., Nguyen B., Osen E.G., Bach C., Chan H.,
RA   Barnett J.;
RT   "Expression of human dopamine beta-hydroxylase in Drosophila Schneider 2
RT   cells.";
RL   Biochem. J. 313:57-64(1996).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=7961964; DOI=10.1016/s0021-9258(18)43941-5;
RA   Kobayashi K., Morita S., Mizuguchi T., Sawada H., Yamada K., Nagatsu I.,
RA   Fujita K., Nagatsu T.;
RT   "Functional and high level expression of human dopamine beta-hydroxylase in
RT   transgenic mice.";
RL   J. Biol. Chem. 269:29725-29731(1994).
RN   [7]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-184.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [8]
RP   GLYCOSYLATION AT ASN-184.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [9]
RP   FUNCTION, AND PATHWAY.
RX   PubMed=27148966; DOI=10.1371/journal.pone.0154864;
RA   Cubells J.F., Schroeder J.P., Barrie E.S., Manvich D.F., Sadee W., Berg T.,
RA   Mercer K., Stowe T.A., Liles L.C., Squires K.E., Mezher A., Curtin P.,
RA   Perdomo D.L., Szot P., Weinshenker D.;
RT   "Human bacterial artificial chromosome (BAC) transgenesis fully rescues
RT   noradrenergic function in dopamine beta-hydroxylase knockout mice.";
RL   PLoS ONE 11:E0154864-E0154864(2016).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 40-617 IN COMPLEX WITH COPPER
RP   IONS, SUBUNIT, DISULFIDE BONDS, GLYCOSYLATION AT ASN-64; ASN-184 AND
RP   ASN-566, AND COFACTOR.
RX   PubMed=27152332; DOI=10.1126/sciadv.1500980;
RA   Vendelboe T.V., Harris P., Zhao Y., Walter T.S., Harlos K., El Omari K.,
RA   Christensen H.E.;
RT   "The crystal structure of human dopamine beta-hydroxylase at 2.9 A
RT   resolution.";
RL   Sci. Adv. 2:E1500980-E1500980(2016).
RN   [11]
RP   VARIANT SER-318.
RX   PubMed=10490716;
RX   DOI=10.1002/(sici)1096-8628(19991015)88:5<557::aid-ajmg22>3.0.co;2-f;
RA   Williams H.J., Bray N., Murphy K.C., Cardno A.G., Jones L.A., Owen M.J.;
RT   "No evidence for allelic association between schizophrenia and a functional
RT   variant of the human dopamine beta-hydroxylase gene (DBH).";
RL   Am. J. Med. Genet. 88:557-559(1999).
RN   [12]
RP   VARIANTS SER-318 AND CYS-549.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [13]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [14]
RP   VARIANTS THR-211 AND SER-318.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for blood-
RT   pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [15]
RP   VARIANTS ORTHYP1 MET-101; GLU-114 AND ASN-345.
RX   PubMed=11857564; DOI=10.1002/ajmg.10196.abs;
RA   Kim C.-H., Zabetian C.P., Cubells J.F., Cho S., Biaggioni I., Cohen B.M.,
RA   Robertson D., Kim K.-S.;
RT   "Mutations in the dopamine beta-hydroxylase gene are associated with human
RT   norepinephrine deficiency.";
RL   Am. J. Med. Genet. 108:140-147(2002).
CC   -!- FUNCTION: Conversion of dopamine to noradrenaline.
CC       {ECO:0000269|PubMed:27148966, ECO:0000269|PubMed:3443096,
CC       ECO:0000269|PubMed:7961964, ECO:0000269|PubMed:8546710}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dopamine + 2 L-ascorbate + O2 = (R)-noradrenaline + H2O + 2
CC         monodehydro-L-ascorbate radical; Xref=Rhea:RHEA:19117,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15379, ChEBI:CHEBI:38290,
CC         ChEBI:CHEBI:59513, ChEBI:CHEBI:59905, ChEBI:CHEBI:72587;
CC         EC=1.14.17.1; Evidence={ECO:0000269|PubMed:3443096,
CC         ECO:0000269|PubMed:7961964, ECO:0000269|PubMed:8546710};
CC   -!- COFACTOR:
CC       Name=Cu(2+); Xref=ChEBI:CHEBI:29036;
CC         Evidence={ECO:0000269|PubMed:8546710, ECO:0000305|PubMed:27152332};
CC       Note=Binds 2 copper ions per subunit. {ECO:0000305|PubMed:27152332};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.8 mM for tyramine {ECO:0000269|PubMed:8546710};
CC       pH dependence:
CC         Optimum pH is 5.2. {ECO:0000269|PubMed:8546710};
CC   -!- PATHWAY: Catecholamine biosynthesis; (R)-noradrenaline biosynthesis;
CC       (R)-noradrenaline from dopamine: step 1/1.
CC       {ECO:0000269|PubMed:27148966, ECO:0000269|PubMed:3443096,
CC       ECO:0000269|PubMed:8546710}.
CC   -!- SUBUNIT: Homotetramer; composed of two disulfide-linked dimers.
CC       {ECO:0000269|PubMed:27152332}.
CC   -!- INTERACTION:
CC       P09172; P00352: ALDH1A1; NbExp=3; IntAct=EBI-8589586, EBI-752170;
CC       P09172; P63010-2: AP2B1; NbExp=3; IntAct=EBI-8589586, EBI-11529439;
CC       P09172; Q04656: ATP7A; NbExp=2; IntAct=EBI-8589586, EBI-7706409;
CC       P09172; Q8WUW1: BRK1; NbExp=3; IntAct=EBI-8589586, EBI-2837444;
CC       P09172; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-8589586, EBI-350590;
CC       P09172; Q71DI3: H3C15; NbExp=3; IntAct=EBI-8589586, EBI-750650;
CC       P09172; P61978: HNRNPK; NbExp=3; IntAct=EBI-8589586, EBI-304185;
CC       P09172; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-8589586, EBI-714379;
CC       P09172; Q92876: KLK6; NbExp=3; IntAct=EBI-8589586, EBI-2432309;
CC       P09172; P08727: KRT19; NbExp=3; IntAct=EBI-8589586, EBI-742756;
CC       P09172; Q14693: LPIN1; NbExp=3; IntAct=EBI-8589586, EBI-5278370;
CC       P09172; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-8589586, EBI-22310682;
CC       P09172; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-8589586, EBI-25830200;
CC       P09172; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-8589586, EBI-9090282;
CC       P09172; Q9ULX5: RNF112; NbExp=3; IntAct=EBI-8589586, EBI-25829984;
CC       P09172; Q96D59: RNF183; NbExp=3; IntAct=EBI-8589586, EBI-743938;
CC       P09172; Q8N6K7-2: SAMD3; NbExp=3; IntAct=EBI-8589586, EBI-11528848;
CC       P09172; Q8IUW3: SPATA2L; NbExp=3; IntAct=EBI-8589586, EBI-2510414;
CC       P09172; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-8589586, EBI-11525489;
CC       P09172; Q9GZS3: WDR61; NbExp=3; IntAct=EBI-8589586, EBI-358545;
CC   -!- SUBCELLULAR LOCATION: [Soluble dopamine beta-hydroxylase]: Cytoplasmic
CC       vesicle, secretory vesicle lumen {ECO:0000269|PubMed:7961964}.
CC       Cytoplasmic vesicle, secretory vesicle, chromaffin granule lumen
CC       {ECO:0000269|PubMed:7961964}. Secreted {ECO:0000269|PubMed:7961964,
CC       ECO:0000269|PubMed:8546710}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, secretory vesicle membrane
CC       {ECO:0000269|PubMed:7961964}; Single-pass type II membrane protein
CC       {ECO:0000305}. Cytoplasmic vesicle, secretory vesicle, chromaffin
CC       granule membrane {ECO:0000269|PubMed:7961964}; Single-pass type II
CC       membrane protein {ECO:0000305}.
CC   -!- INDUCTION: Activity is enhanced by nerve growth factor (in superior
CC       cervical ganglia and adrenal medulla). Trans-synaptic stimulation with
CC       reserpine, acetylcholine and glucocorticoids.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:27152332,
CC       ECO:0000269|PubMed:8546710}.
CC   -!- PTM: Proteolytic cleavage after the membrane-anchor leads to the
CC       release of the soluble form. {ECO:0000250|UniProtKB:P15101}.
CC   -!- POLYMORPHISM: There are two main alleles of DBH: DBH-A with Ala-318 and
CC       DBH-B with Ser-318 (PubMed:10490716, PubMed:10391209, PubMed:10391210).
CC       {ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10391210,
CC       ECO:0000269|PubMed:10490716}.
CC   -!- DISEASE: Orthostatic hypotension 1 (ORTHYP1) [MIM:223360]: A form of
CC       orthostatic hypotension due to congenital dopamine beta-hydroxylase
CC       deficiency. Orthostatic hypotension, also known as postural
CC       hypotension, is a finding defined as a 20-mm Hg decrease in systolic
CC       pressure or a 10-mm Hg decrease in diastolic pressure occurring 3
CC       minutes after a person has risen from supine to standing. Symptoms
CC       include dizziness, blurred vision, and sometimes syncope. ORTHYP1 is an
CC       autosomal recessive condition apparent from infancy or early childhood
CC       and characterized by low plasma and urinary levels of norepinephrine
CC       and epinephrine, and episodic hypoglycemia.
CC       {ECO:0000269|PubMed:11857564}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the copper type II ascorbate-dependent
CC       monooxygenase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH17174.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA31631.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA31632.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA68285.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Dopamine beta hydroxylase entry;
CC       URL="https://en.wikipedia.org/wiki/Dopamine_beta_hydroxylase";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL365494; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Y00096; CAA68285.1; ALT_INIT; mRNA.
DR   EMBL; BC017174; AAH17174.1; ALT_INIT; mRNA.
DR   EMBL; X13255; CAA31631.1; ALT_INIT; mRNA.
DR   EMBL; X13256; CAA31632.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6977.2; -.
DR   PIR; S03020; S03020.
DR   RefSeq; NP_000778.3; NM_000787.3.
DR   PDB; 4ZEL; X-ray; 2.90 A; A/B=40-617.
DR   PDBsum; 4ZEL; -.
DR   AlphaFoldDB; P09172; -.
DR   SMR; P09172; -.
DR   BioGRID; 107989; 19.
DR   IntAct; P09172; 23.
DR   MINT; P09172; -.
DR   STRING; 9606.ENSP00000376776; -.
DR   BindingDB; P09172; -.
DR   ChEMBL; CHEMBL3102; -.
DR   DrugBank; DB00126; Ascorbic acid.
DR   DrugBank; DB06774; Capsaicin.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB05394; Corticorelin.
DR   DrugBank; DB00822; Disulfiram.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00968; Methyldopa.
DR   DrugBank; DB00550; Propylthiouracil.
DR   DrugCentral; P09172; -.
DR   GuidetoPHARMACOLOGY; 2486; -.
DR   GlyConnect; 1933; 9 N-Linked glycans (1 site).
DR   GlyCosmos; P09172; 3 sites, 9 glycans.
DR   GlyGen; P09172; 4 sites, 9 N-linked glycans (1 site).
DR   iPTMnet; P09172; -.
DR   PhosphoSitePlus; P09172; -.
DR   SwissPalm; P09172; -.
DR   BioMuta; DBH; -.
DR   DMDM; 158517849; -.
DR   MassIVE; P09172; -.
DR   PaxDb; P09172; -.
DR   PeptideAtlas; P09172; -.
DR   ProteomicsDB; 52205; -.
DR   Antibodypedia; 881; 572 antibodies from 47 providers.
DR   DNASU; 1621; -.
DR   Ensembl; ENST00000393056.8; ENSP00000376776.2; ENSG00000123454.12.
DR   GeneID; 1621; -.
DR   KEGG; hsa:1621; -.
DR   MANE-Select; ENST00000393056.8; ENSP00000376776.2; NM_000787.4; NP_000778.3.
DR   UCSC; uc004cel.4; human.
DR   AGR; HGNC:2689; -.
DR   CTD; 1621; -.
DR   DisGeNET; 1621; -.
DR   GeneCards; DBH; -.
DR   GeneReviews; DBH; -.
DR   HGNC; HGNC:2689; DBH.
DR   HPA; ENSG00000123454; Group enriched (adrenal gland, brain).
DR   MalaCards; DBH; -.
DR   MIM; 223360; phenotype.
DR   MIM; 609312; gene.
DR   neXtProt; NX_P09172; -.
DR   OpenTargets; ENSG00000123454; -.
DR   Orphanet; 230; Dopamine beta-hydroxylase deficiency.
DR   PharmGKB; PA136; -.
DR   VEuPathDB; HostDB:ENSG00000123454; -.
DR   eggNOG; KOG3568; Eukaryota.
DR   GeneTree; ENSGT00530000063085; -.
DR   HOGENOM; CLU_017939_3_0_1; -.
DR   InParanoid; P09172; -.
DR   OMA; WVRKDYQ; -.
DR   OrthoDB; 37880at2759; -.
DR   PhylomeDB; P09172; -.
DR   TreeFam; TF320698; -.
DR   BioCyc; MetaCyc:MON66-381; -.
DR   BRENDA; 1.14.17.1; 2681.
DR   PathwayCommons; P09172; -.
DR   Reactome; R-HSA-209905; Catecholamine biosynthesis.
DR   SignaLink; P09172; -.
DR   SIGNOR; P09172; -.
DR   UniPathway; UPA00748; UER00735.
DR   BioGRID-ORCS; 1621; 14 hits in 1158 CRISPR screens.
DR   ChiTaRS; DBH; human.
DR   GeneWiki; Dopamine_beta_hydroxylase; -.
DR   GenomeRNAi; 1621; -.
DR   Pharos; P09172; Tchem.
DR   PRO; PR:P09172; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P09172; protein.
DR   Bgee; ENSG00000123454; Expressed in right lobe of liver and 103 other tissues.
DR   ExpressionAtlas; P09172; baseline and differential.
DR   Genevisible; P09172; HS.
DR   GO; GO:0034451; C:centriolar satellite; IDA:HPA.
DR   GO; GO:0034466; C:chromaffin granule lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0042584; C:chromaffin granule membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0034774; C:secretory granule lumen; IDA:UniProtKB.
DR   GO; GO:0030667; C:secretory granule membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0030658; C:transport vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0004500; F:dopamine beta-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0031418; F:L-ascorbic acid binding; IEA:UniProtKB-KW.
DR   GO; GO:0048149; P:behavioral response to ethanol; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0042420; P:dopamine catabolic process; IDA:UniProtKB.
DR   GO; GO:0042596; P:fear response; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0042309; P:homoiothermy; IEA:Ensembl.
DR   GO; GO:0002443; P:leukocyte mediated immunity; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006589; P:octopamine biosynthetic process; IBA:GO_Central.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:2001236; P:regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1904705; P:regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:1905562; P:regulation of vascular endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0048265; P:response to pain; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; IEA:Ensembl.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   CDD; cd09631; DOMON_DOH; 1.
DR   Gene3D; 2.60.120.230; -; 1.
DR   Gene3D; 2.60.120.310; Copper type II, ascorbate-dependent monooxygenase, N-terminal domain; 1.
DR   InterPro; IPR014784; Cu2_ascorb_mOase-like_C.
DR   InterPro; IPR020611; Cu2_ascorb_mOase_CS-1.
DR   InterPro; IPR014783; Cu2_ascorb_mOase_CS-2.
DR   InterPro; IPR000323; Cu2_ascorb_mOase_N.
DR   InterPro; IPR036939; Cu2_ascorb_mOase_N_sf.
DR   InterPro; IPR024548; Cu2_monoox_C.
DR   InterPro; IPR000945; DBH-like.
DR   InterPro; IPR045266; DOH_DOMON.
DR   InterPro; IPR005018; DOMON_domain.
DR   InterPro; IPR008977; PHM/PNGase_F_dom_sf.
DR   InterPro; IPR028460; Tbh/DBH.
DR   PANTHER; PTHR10157; DOPAMINE BETA HYDROXYLASE RELATED; 1.
DR   PANTHER; PTHR10157:SF29; DOPAMINE BETA-HYDROXYLASE; 1.
DR   Pfam; PF03712; Cu2_monoox_C; 1.
DR   Pfam; PF01082; Cu2_monooxygen; 1.
DR   Pfam; PF03351; DOMON; 1.
DR   PRINTS; PR00767; DBMONOXGNASE.
DR   SMART; SM00664; DoH; 1.
DR   SUPFAM; SSF49742; PHM/PNGase F; 2.
DR   PROSITE; PS00084; CU2_MONOOXYGENASE_1; 1.
DR   PROSITE; PS00085; CU2_MONOOXYGENASE_2; 1.
DR   PROSITE; PS50836; DOMON; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Catecholamine biosynthesis; Copper; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Membrane; Metal-binding; Monooxygenase; Oxidoreductase; Reference proteome;
KW   Secreted; Signal-anchor; Transmembrane; Transmembrane helix; Vitamin C.
FT   CHAIN           1..617
FT                   /note="Dopamine beta-hydroxylase"
FT                   /id="PRO_0000006356"
FT   CHAIN           40..617
FT                   /note="Soluble dopamine beta-hydroxylase"
FT                   /id="PRO_0000308209"
FT   TOPO_DOM        1..16
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        17..37
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        38..617
FT                   /note="Intragranular"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          57..173
FT                   /note="DOMON"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00246"
FT   REGION          590..617
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        591..606
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        230
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        412
FT                   /evidence="ECO:0000255"
FT   BINDING         262
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="A"
FT                   /evidence="ECO:0000250"
FT   BINDING         263
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="A"
FT                   /evidence="ECO:0000250"
FT   BINDING         333
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="A"
FT                   /evidence="ECO:0000250"
FT   BINDING         412
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="B"
FT                   /evidence="ECO:0000305|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   BINDING         414
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="B"
FT                   /evidence="ECO:0000305|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   BINDING         487
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /ligand_label="B"
FT                   /evidence="ECO:0000305|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   SITE            39..40
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250|UniProtKB:P15101"
FT   CARBOHYD        64
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   CARBOHYD        184
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   CARBOHYD        566
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        154..596
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        232..283
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        269..295
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        390..503
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        394..565
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        466..488
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        528
FT                   /note="Interchain (with C-530)"
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   DISULFID        530
FT                   /note="Interchain (with C-528)"
FT                   /evidence="ECO:0000269|PubMed:27152332,
FT                   ECO:0007744|PDB:4ZEL"
FT   VARIANT         12
FT                   /note="G -> S (in dbSNP:rs5318)"
FT                   /id="VAR_048838"
FT   VARIANT         101
FT                   /note="V -> M (in ORTHYP1; dbSNP:rs267606760)"
FT                   /evidence="ECO:0000269|PubMed:11857564"
FT                   /id="VAR_022758"
FT   VARIANT         114
FT                   /note="D -> E (in ORTHYP1; dbSNP:rs77576840)"
FT                   /evidence="ECO:0000269|PubMed:11857564"
FT                   /id="VAR_022759"
FT   VARIANT         181
FT                   /note="E -> Q (in dbSNP:rs5319)"
FT                   /id="VAR_014706"
FT   VARIANT         211
FT                   /note="A -> T (in dbSNP:rs5320)"
FT                   /evidence="ECO:0000269|PubMed:10391210,
FT                   ECO:0000269|PubMed:3443096"
FT                   /id="VAR_013947"
FT   VARIANT         239
FT                   /note="K -> N (in dbSNP:rs5321)"
FT                   /id="VAR_014707"
FT   VARIANT         250
FT                   /note="E -> Q (in dbSNP:rs5323)"
FT                   /id="VAR_014708"
FT   VARIANT         290
FT                   /note="D -> N (in dbSNP:rs5324)"
FT                   /id="VAR_014709"
FT   VARIANT         317
FT                   /note="L -> P (in dbSNP:rs5325)"
FT                   /id="VAR_014710"
FT   VARIANT         318
FT                   /note="A -> S (in allele DBH-B; dbSNP:rs4531)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10391210, ECO:0000269|PubMed:10490716"
FT                   /id="VAR_002196"
FT   VARIANT         345
FT                   /note="D -> N (in ORTHYP1; dbSNP:rs267606761)"
FT                   /evidence="ECO:0000269|PubMed:11857564"
FT                   /id="VAR_022760"
FT   VARIANT         549
FT                   /note="R -> C (in dbSNP:rs6271)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:3443096"
FT                   /id="VAR_013948"
FT   CONFLICT        505
FT                   /note="S -> T (in Ref. 2; CAA68285 and 4;
FT                   CAA31631/CAA31632)"
FT                   /evidence="ECO:0000305"
FT   STRAND          48..52
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          58..66
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   TURN            67..70
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          71..80
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          83..93
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          98..104
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          111..117
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          130..138
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          143..151
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          166..173
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          191..195
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          212..217
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          225..236
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          244..252
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   TURN            255..260
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          261..268
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          279..284
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          286..288
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          290..294
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          297..303
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          313..319
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          327..335
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          348..356
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          359..361
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          363..369
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          375..377
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          382..390
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   HELIX           392..398
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          404..412
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          417..426
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          429..439
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          448..456
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          461..468
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          477..482
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          489..496
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          499..507
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   HELIX           509..522
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   HELIX           535..539
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   HELIX           546..558
FT                   /evidence="ECO:0007829|PDB:4ZEL"
FT   STRAND          561..567
FT                   /evidence="ECO:0007829|PDB:4ZEL"
SQ   SEQUENCE   617 AA;  69065 MW;  4D5586F0E358885D CRC64;
     MPALSRWASL PGPSMREAAF MYSTAVAIFL VILVAALQGS APRESPLPYH IPLDPEGSLE
     LSWNVSYTQE AIHFQLLVRR LKAGVLFGMS DRGELENADL VVLWTDGDTA YFADAWSDQK
     GQIHLDPQQD YQLLQVQRTP EGLTLLFKRP FGTCDPKDYL IEDGTVHLVY GILEEPFRSL
     EAINGSGLQM GLQRVQLLKP NIPEPELPSD ACTMEVQAPN IQIPSQETTY WCYIKELPKG
     FSRHHIIKYE PIVTKGNEAL VHHMEVFQCA PEMDSVPHFS GPCDSKMKPD RLNYCRHVLA
     AWALGAKAFY YPEEAGLAFG GPGSSRYLRL EVHYHNPLVI EGRNDSSGIR LYYTAKLRRF
     NAGIMELGLV YTPVMAIPPR ETAFILTGYC TDKCTQLALP PSGIHIFASQ LHTHLTGRKV
     VTVLVRDGRE WEIVNQDNHY SPHFQEIRML KKVVSVHPGD VLITSCTYNT EDRELATVGG
     FGILEEMCVN YVHYYPQTQL ELCKSAVDAG FLQKYFHLIN RFNNEDVCTC PQASVSQQFT
     SVPWNSFNRD VLKALYSFAP ISMHCNKSSA VRFQGEWNLQ PLPKVISTLE EPTPQCPTSQ
     GRSPAGPTVV SIGGGKG
//
